{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T14:00:24Z","timestamp":1693144824775},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ygyno.2005.09.043","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T07:48:22Z","timestamp":1131004102000},"page":"114-119","source":"Crossref","is-referenced-by-count":4,"title":["Sequential gemcitabine\u2013carboplatin followed by paclitaxel\u2013carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study"],"prefix":"10.1016","volume":"101","author":[{"given":"Johanna U.","family":"M\u00e4enp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seija E.","family":"Gr\u00e9nman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyrki T.","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapio A.","family":"Kuoppala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arto O.","family":"Leminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla S.","family":"Puistola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi M.","family":"Vuolo-Meril\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merja H.","family":"Yliskoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2005.09.043_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2005.09.043_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2005.09.043_bib3","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel vs. carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2005.09.043_bib5","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2005.09.043_bib6","first-page":"1379a","article-title":"Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO Stages IIB\u2013IV (Abstract)","volume":"18","author":"Hansen","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib9","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2005.09.043_bib11","first-page":"689","article-title":"A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma","volume":"56","author":"Righetti","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.09.043_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","article-title":"Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis","volume":"2","author":"Wahl","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2005.09.043_bib13","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1200\/JCO.2000.18.23.3936","article-title":"p53 gene status and response to platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma","volume":"18","author":"Lavarino","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2005.09.043_bib15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian cancer to initial chemotherapy according to S-CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian cancer during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2005.09.043_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(01)00340-9","article-title":"Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies","volume":"38","author":"Calvert","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.09.043_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(92)90043-I","article-title":"Prognostic value of CA 125 in advanced ovarian cancer","volume":"44","author":"Mogensen","year":"1992","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805008413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805008413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T18:04:32Z","timestamp":1549562672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825805008413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0090825805008413"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2005.09.043","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}